Earthquake Rattles Life Sciences Companies Across Sectors; MHLW Response Could Impact Pricing And Inspections
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The recent natural disasters in Japan create much uncertainty around various sectors in Japan's healthcare industry, but analysts are cautiously optimistic about most companies in the pharma, biotech, device and diagnostic industries ability to recover quickly. But these companies rely on Japan's Pharmaceuticals and Medical Devices Agency to operate in the country, and the agency's recovery and response to the crisis may have implications for price revisions and compliance inspections